PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Korean Journal of Ophthalmology10.3341/kjo.2018.00112018326451Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical OutcomesHyun Goo Kang, Eun Young Choi, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sung Chul Lee, Min Kimhttps://synapse.koreamed.org/pdf/10.3341/kjo.2018.0011, https://synapse.koreamed.org/DOIx.php?id=10.3341/kjo.2018.0011, https://synapse.koreamed.org/DOIx.php?id=10.3341/kjo.2018.0011
10.21203/rs.3.rs-1560023/v22022Treatment for non-type 1 retinopathy of prematurity by intravitreal injection of anti-vascular endothelial growth factor drugsHaitao Zhang, Xin Yang, Fangfang Zheng, Xiangke Yin, Suhua Wanhttps://www.researchsquare.com/article/rs-1560023/v2, https://www.researchsquare.com/article/rs-1560023/v2.html
Human Care Journal10.32883/hcj.v6i2.1191202162358ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA RETINOPATHY OF PREMATURITYNasyayya Akbari Nazarhttps://ojs.fdk.ac.id/index.php/humancare/article/viewFile/1191/pdf, https://ojs.fdk.ac.id/index.php/humancare/article/viewFile/1191/pdf
10.21203/rs.3.rs-1560023/v12022Treatment for non-type 1 retinopathy of prematurity by intravitreal injection of anti-vascular endothelial growth factor drugsHaitao Zhang, Xin Yang, Fangfang Zheng, Xiangke Yin, Suhua Wan, Yingying Xuhttps://www.researchsquare.com/article/rs-1560023/v1, https://www.researchsquare.com/article/rs-1560023/v1.html
Ophthalmology10.1016/j.ophtha.2018.08.0182018125121967-1968Exploring the Limits: The Challenge of Finding the Right Dose for Anti–Vascular Endothelial Growth Factor Treatment in Retinopathy of PrematurityAndreas Stahlhttps://api.elsevier.com/content/article/PII:S0161642018319924?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0161642018319924?httpAccept=text/plain
American Journal of Ophthalmology10.1016/j.ajo.2020.12.0182021231213Erratum to Retinopathy of Prematurity: Evolving Treatment with anti-Vascular Endothelial Growth Factor. Am J Ophthalmol 2020;218:208-213.https://api.elsevier.com/content/article/PII:S0002939420306760?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0002939420306760?httpAccept=text/plain
Ophthalmology10.1016/j.ophtha.2018.04.0182018125101485-1487How Does the Standard of Care Evolve? Anti–Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an ExampleMichael F. Chianghttps://api.elsevier.com/content/article/PII:S0161642018305207?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0161642018305207?httpAccept=text/plain
Neonatology10.1159/00036513220141063254-260Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time ComeAndreas Stahl, Ann Hellstrom, Lois E.H. Smithhttps://www.karger.com/Article/Pdf/365132, https://www.karger.com/Article/Pdf/365132
Pediatric Health, Medicine and Therapeutics10.2147/phmt.s3915912023Volume 1459-69Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income CountriesMangat Ram Dogra, Anand Vinekarhttps://www.dovepress.com/getfile.php?fileID=87502, https://www.dovepress.com/getfile.php?fileID=87502
Early Human Development10.1016/j.earlhumdev.2012.09.01920128812937-941Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitorsHelen A. Mintz-Hittnerhttps://api.elsevier.com/content/article/PII:S0378378212002411?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0378378212002411?httpAccept=text/plain